Primerica: The Term-Life Turnaround Keeps Missing Its Cue
Record investment sales and a 34% ROE are real, but the term-life inflection management promised is now a guidance cut and an actuarial reset.
PRI · Earnings Call · 2026-11-05
Two businesses, two tapes
Primerica's third quarter was another demonstration of why the company is hard to pigeonhole. The distribution engine that sells term life and investment products to middle-income families produced $902 million of adjusted operating revenue, up 8%, and diluted adjusted operating EPS of $6.77, up 7%. But adjusted net operating income rose only 2%, to $209 million, because the prior-year quarter contained a much larger actuarial remeasurement gain. That is the tell: the headline is fine, the mix is not. Term Life is still shrinking; Investments is still compounding.
The term-life inflection that keeps sliding
The prior call set a bar: term-life policies issued were guided to fall mid-single digits for the year, which implied growth in the back half. The current call cuts that to a full-year decline of 8% to 10%, with fourth-quarter issued policies down low single digits. Recruiting fell 10% year over year, new life licenses fell 14%, and the sales force is expected to end 2026 down about 3%. This is not a one-quarter wobble. It is a distribution pipeline problem showing up in the recruiting activity numbers. Glenn Williams was direct that the hoped-for turn is late: “We're probably a couple of quarters later than I anticipated earlier in the year. But we are seeing some stability. We're finding our footing.” — Glenn Williams, CEO · 2026-11-05 His metaphor for the sales force is telling:
We tend to grow our sales force in stair steps. So we'll get to a peak and we'll take a breath, the horses will take a rest, and then, we'll get them ready to run again.
The problem is that the market has been waiting for the next stair step since at least the second quarter, when management said it expected strengthening comparisons and firmer footing. “we do expect some strengthening in our comparisons to previous years... we believe we're finding some firmer footing” — Glenn J. Williams, Chief Executive Officer · 2026-08-06 That makes the current guidance cut more than macro noise. The company's own prior framing assumed an inflection; the current numbers do not yet show one.
The fresher issue: lapse assumptions
The more company-specific signal in this report is not sales; it is the annual actuarial review. Primerica completed its LDTI assumption review and raised long-term lapse assumptions, producing a $9 million remeasurement gain versus $23 million a year earlier. Term Life pretax income fell 12%, and the segment operating margin compressed to 21.8% from 25.4%. The CFO was explicit: “These assumption changes reflected overall higher lapses and ongoing favorable mortality.” — Tracy Tan, CFO · 2026-11-05 That is an earnings-base reset, not a timing issue. The topic now dominates the company keyword set: lapse rates and high lapse are fresh top-ranked themes, while negative trend is the phrase management is using to describe the sales trajectory it once expected to moderate. This is consistent with prior disclosures that pandemic-era policies are running off; Tracy Tan previously noted “some of the policies brought on during the pandemic period may not be the most committed buyers” — Tracy Tan, Chief Financial Officer · 2026-05-07. The difference is that the runoff is now embedded in the long-term assumption set, which lowers the forward margin runway.
Investments are carrying the company
The offset is genuine. Investment and Savings Products delivered another record quarter: total securities sales rose 19%, variable annuities 29%, managed accounts 27%, and mutual funds 8%. Assets under management reached $140 billion, up 10%, with $407 million of net client flows. Asset-based revenue grew 21%, outpacing the 14% growth in average client values because of favorable product mix. Williams noted “we've experienced 12 consecutive quarters of not just growth, but double-digit growth in our ISP sales.” — Glenn Williams, CEO · 2026-11-05 That is the strongest part of the story, and it is why investment sales remain the company's growth engine. But guidance for fourth-quarter investment sales is only mid-single digits, with full-year growth mid- to high teens. Management is signaling harder comparisons, not a new deceleration. The global tape adds an interesting cross-check: the middle-income consumer basket is up roughly 18.5% over 30 days across names like LEVI, AAP, KDP, MCD, and KSS. The market is beginning to price a middle-income recovery. Primerica's term-life sales do not confirm it yet. If that recovery is real, term life should eventually follow; if it is not, the investment strength is more about aging clients and money in motion than broad household health.
Capital, rates, and the 2027 calendar
The balance sheet remains a fortress: $600 million of holding-company cash and available-for-sale securities, an estimated RBC ratio of 445%, and $122 million of buybacks plus $37 million of dividends in the quarter. Year-to-date capital returned was $511 million. effective net cash was $4.0 billion, and interest coverage is high. The weak spot is that the unrealized loss in the investment portfolio widened to $280 million from $140 million as rates rose; management says it has the intent and ability to hold to maturity. Expenses rose 9% in the quarter, with fourth-quarter growth guided to about 10% as Primerica invests in front-end technology, client experience, and growth initiatives. The 50th anniversary and the July 2027 convention are real potential catalysts, but they are 2027 events. At roughly 11x trailing earnings, the stock is not expensive; it is also down 11.5% from its August peak and flat over the past 90 days. The bar is low. The missing piece is still distribution. Until recruiting and licensing stabilize, buybacks are financial engineering around a shrinking sales force. The fourth-quarter issued-policy guide and the 2027 convention build are the two data points that matter next.